Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BioAtla, Inc. (BCAB : NSDQ)

• Company Description    BioAtla Inc. is a clinical-stage biopharmaceutical company. It engages in developing a novel class of antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla Inc. is based in SAN DIEGO. Number of Employees: 41

• Price / Volume Information    Yesterday's Closing Price: $3.69 Daily Weekly Monthly 20 Day Moving Average: 31,082 shares Shares Outstanding: 1.66 (millions) Market Capitalization: $6.11 (millions) Beta: 0.81 52 Week High: $71.50 52 Week Low: $3.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.49% -31.98% 12 Week -68.91% -71.26% Year To Date -87.00% -88.29%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11085 TORREYANA ROAD - SAN DIEGO,CA 92121 USA ph: 858-558-0708 fax: - investors@bioatla.com http://www.bioatla.com

• General Corporate Information    Officers Jay M. Short - Chief Executive Officer and Director Christian Vasquez - Chief Financial Officer Scott Smith - Director Lawrence Steinman, - Director Mary Ann Gray - Director Peer Information BioAtla, Inc. (CORR.) BioAtla, Inc. (RSPI) BioAtla, Inc. (CGXP) BioAtla, Inc. (BGEN) BioAtla, Inc. (GTBP) BioAtla, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09077B203 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/26/26 Share - Related Items Shares Outstanding: 1.66 Most Recent Split Date: 4.00 (0.02:1) Beta: 0.81 Market Capitalization: $6.11 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 50.00% vs. Previous Quarter: 40.74% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - -307.62 12/31/25 - -257.22 09/30/25 - -200.66 Current Ratio 03/31/26 - 0.15 12/31/25 - 0.37 09/30/25 - 0.54 Quick Ratio 03/31/26 - - 12/31/25 - 0.37 09/30/25 - 0.54 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - -2,530.85 12/31/25 - -2,980.35 09/30/25 - - Book Value 03/31/26 - -22.52 12/31/25 - -28.51 09/30/25 - -26.57 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©